NDAORALSOLUTION
Approved
Feb 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
NORLIQVA (amlodipine) by BrilliantStrings Therapeutics is calcium channel antagonists [moa]. Approved for hypertension. First approved in 2022.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORLIQVA is an oral calcium channel blocker (amlodipine) approved in 2022 for hypertension and multiple cardiovascular and metabolic indications including dyslipidemia, left ventricular hypertrophy, stroke prevention, and diabetes. It works by antagonizing L-type calcium channels to reduce vascular smooth muscle contraction and lower blood pressure. The product is formulated as a solution, enabling flexible dosing for diverse patient populations.
$299KPart D
Peak14.8 years to LOEEarly-stage peak-phase product with minimal Medicare Part D penetration ($299K spending, 451 claims in 2023), indicating significant growth runway and potential team expansion opportunities.
Mechanism of Action
Calcium Channel Antagonists
Pharmacologic Class:
Dihydropyridine Calcium Channel Blocker
Indications (1)
Clinical Trials (20)
Bioequivalence Study of Amlodipine/Valsartan 10/160 mg Film Coated Tablets
Started May 2024
48 enrolled
Healthy Volunteer
Evaluation of the Antihypertensive effectIveness, Tolerability, and Adherence With Amlodipine/ Indapamide/ Perindopril Triple Single-pill Combination in Hypertensive Patients Without Concomitant Antihypertensive Therapy (TRIPTYCH)
Started May 2024
396 enrolled
Arterial HypertensionHTN
Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy
Started Apr 2024
718 enrolled
Hypertension
Description of the Effectiveness, Safety, Tolerability and Adherence to Amlodipine/Atorvastatin/Perindopril Single Pill Combination Treatment in Patients With Arterial Hypertension and Dyslipidemia (TARGET)
Started Apr 2023
409 enrolled
Arterial HypertensionHTN
S-amlodipine in Essential HypertensIon and Assessment of Blood Pressure Targets Achievement
Started Feb 2023
5,000 enrolled
Essential Hypertension
Worked on NORLIQVA at BrilliantStrings Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.